Thor-Henrik Brodtkorb

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 8

Top Topics

Ejection Fraction

Top Venues

Journal of medical economics

This page only lists publications with an associated author ORCID identifier.

Publications

Thor-Henrik Brodtkorb, Christopher Knight, Farzam Kamgar, Siguroli Teitsson, Murat Kurt, Miraj Y Patel, Tayla Poretta, Ronac Mamtani, Stephen Palmer
Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective. Journal of medical economics 27 (1) (2024)
Siguroli Teitsson, Thor-Henrik Brodtkorb, Murat Kurt, Miraj Y Patel, Tayla Poretta, Christopher Knight, Farzam Kamgar, Stephen Palmer
Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo. Journal of medical economics 27 (1) (2024)
Siguroli Teitsson, Thor-Henrik Brodtkorb, Murat Kurt, Miraj Y Patel, Tayla Poretta, Christopher Knight, Farzam Kamgar, Stephen Palmer
Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo. Journal of medical economics 27 (1) (2024)
Thor-Henrik Brodtkorb, Christopher Knight, Farzam Kamgar, Siguroli Teitsson, Murat Kurt, Miraj Y Patel, Tayla Poretta, Ronac Mamtani, Stephen Palmer
Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective. Journal of medical economics 27 (1) (2024)
Thor-Henrik Brodtkorb, Christopher Knight, Farzam Kamgar, Siguroli Teitsson, Murat Kurt, Miraj Y Patel, Tayla Poretta, Ronac Mamtani, Stephen Palmer
Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective. Journal of medical economics 27 (1) (2024)
Thor-Henrik Brodtkorb, Christopher Knight, Farzam Kamgar, Siguroli Teitsson, Murat Kurt, Miraj Y Patel, Tayla Poretta, Ronac Mamtani, Stephen Palmer
Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective. Journal of medical economics (2024)
Siguroli Teitsson, Thor-Henrik Brodtkorb, Murat Kurt, Miraj Y Patel, Tayla Poretta, Christopher Knight, Farzam Kamgar, Stephen Palmer
Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo. Journal of medical economics (2024)
Thor-Henrik Brodtkorb, Christopher Knight, Farzam Kamgar, Siguroli Teitsson, Murat Kurt, Miraj Y Patel, Tayla Poretta, Ronac Mamtani, Stephen Palmer
Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective. Journal of medical economics 27 (1) (2024)